 WESTLAKE VILLAGE, Calif., Nov. 10, 2022 GLOBE NEWSWIRE -- MannKind Corporation Nasdaq: MNKD, a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will present data from two posters on November 10 during the 22nd Annual Diabetes Technology Meetings virtual poster session. 